How concerning is Moderna's latest bad news? From a near-term perspective ... The company's lower guidance has forced me to reevaluate my position. If we assume Moderna only hits the low end ...

Shares of Moderna Inc. fell sharply on Monday after the biotech firm projected a steep decline in 2025 revenues, falling below Wall Street expectations. The company, known for its COVID-19 vaccine ...

Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $ ...

Near term, Moderna is expecting the FDA to make a decision on its next-generation COVID shot mRNA-1283 toward the end of May. Beyond that potential nod, the company is working through the ...

Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Drug maker Moderna's stock plunged more than 17% in pre-market trading on Monday after the company slashed its sales outlook by $1 billion. The company reported product sales of $3 to $3.1 billion ...

In this screen grab taken from the SpaceX broadcast the Starship's Super Heavy Booster is being grabbed as it returns to the launch pad at Starbase near Boca Chica, Texas, on Jan. 16, 2025.

(Bloomberg) -- Moderna Inc. was awarded an additional $590 million from the US government to help the company develop a vaccine aimed at protecting people from bird flu.Most Read from ...

Separately, the UK government purchased 60 million doses of Moderna’s COVID-19 vaccine, which may include an updated booster vaccine candidate against the newer variants like Omicron if ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...